Swarts, Dorian R. A.; Scarpa, Aldo; Corbo, Vincenzo; Van Criekinge, Wim; van Engeland, Manon; Gatti, Gaia; Henfling, Mieke E. R.; Papotti, Mauro; Perren, Aurel; Ramaekers, Frans C. S.; Speel, Ernst-Jan M.; Volante, Marco (2014). MEN1 Gene Mutation and Reduced Expression Are Associated With Poor Prognosis in Pulmonary Carcinoids. Journal of clinical endocrinology and metabolism, 99(2), E374-E378. Endocrine Society 10.1210/jc.2013-2782
Text
jc.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (336kB) |
Context: MEN1 gene alterations have been implicated in lung carcinoids, but their effect on gene expression and disease outcome is unknown. Objective: Our objective was to analyze MEN1 gene and expression anomalies in lung neuroendocrine neoplasms and their correlations with clinicopathologic data and disease outcome. Design: We examined 74 lung neuroendocrine neoplasms including 58 carcinoids and 16 high-grade neuroendocrine carcinomas (HGNECs) for MEN1 mutations (n = 70) and allelic losses (n = 69), promoter hypermethylation (n = 65), and mRNA (n = 74) expression. Results were correlated with disease outcome. Results: MEN1 mutations were found in 7 of 55 (13%) carcinoids and in 1 HGNEC, mostly associated with loss of the second allele. MEN1 decreased expression levels correlated with the presence of mutations (P = .0060) and was also lower in HGNECs than carcinoids (P = .0024). MEN1 methylation was not associated with mRNA expression levels. Patients with carcinoids harboring MEN1 mutation and loss had shorter overall survival (P = .039 and P = .035, respectively) and low MEN1 mRNA levels correlated with distant metastasis (P = .00010) and shorter survival (P = .0071). In multivariate analysis, stage and MEN1 allelic loss were independent predictors of prognosis. Conclusion: Thirteen percent of pulmonary carcinoids harbor MEN1 mutation associated with reduced mRNA expression and poor prognosis. Also in mutation-negative tumors, low MEN1 gene expression correlates with an adverse disease outcome. Hypermethylation was excluded as the underlying mechanism.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Perren, Aurel |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0021-972X |
Publisher: |
Endocrine Society |
Language: |
English |
Submitter: |
Andrea Arnold |
Date Deposited: |
02 Apr 2014 14:55 |
Last Modified: |
05 Dec 2022 14:30 |
Publisher DOI: |
10.1210/jc.2013-2782 |
PubMed ID: |
24276465 |
BORIS DOI: |
10.7892/boris.45136 |
URI: |
https://boris.unibe.ch/id/eprint/45136 |